Get the latest tech news
Dual-target weight-loss drug is 47% more effective than its rival | “Our study shows that treatment with tirzepatide was superior to semaglutide with respect to reduction in body weight and waist circumference."
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out on top.
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. A new study led by Weill Cornell Medicine in New York was the first to undertake a head-to-head comparison of the weight loss effectiveness of semaglutide and tirzepatide, and one of them clearly came out on top. As well as regulating the release of insulin in response to food, GIP receptors play a role in reducing appetite and enhancing feelings of fullness.
Or read this on r/tech
